Stock Traders Buy Large Volume of Intercept Pharmaceuticals Call Options (NASDAQ:ICPT)

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) was the target of some unusual options trading activity on Monday. Stock traders bought 4,542 call options on the stock. This is an increase of 320% compared to the average volume of 1,081 call options.

A number of analysts recently issued reports on the stock. Cowen downgraded shares of Intercept Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $149.00 to $47.00 in a report on Monday. Credit Suisse Group downgraded shares of Intercept Pharmaceuticals from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $137.00 to $59.00 in a report on Monday. Citigroup raised shares of Intercept Pharmaceuticals from a “neutral” rating to a “buy” rating and lowered their price target for the stock from $110.00 to $67.00 in a report on Tuesday. UBS Group downgraded shares of Intercept Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $135.00 to $57.00 in a report on Tuesday. Finally, B. Riley reissued a “buy” rating and set a $97.00 price target on shares of Intercept Pharmaceuticals in a report on Monday. Eighteen equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $81.48.

In other news, Director Paolo Fundaro sold 595,578 shares of the company’s stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $84.60, for a total value of $50,385,898.80. Following the sale, the director now directly owns 19,433 shares of the company’s stock, valued at approximately $1,644,031.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 595,817 shares of company stock worth $50,405,516 over the last ninety days. Insiders own 23.70% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Public Employees Retirement Association of Colorado lifted its holdings in Intercept Pharmaceuticals by 20.9% in the first quarter. Public Employees Retirement Association of Colorado now owns 4,290 shares of the biopharmaceutical company’s stock valued at $270,000 after acquiring an additional 742 shares during the last quarter. Sarissa Capital Management LP lifted its holdings in Intercept Pharmaceuticals by 34.3% in the first quarter. Sarissa Capital Management LP now owns 1,155,000 shares of the biopharmaceutical company’s stock valued at $72,718,000 after acquiring an additional 295,000 shares during the last quarter. Twinbeech Capital LP acquired a new position in Intercept Pharmaceuticals in the first quarter valued at approximately $928,000. Advisor Group Holdings Inc. acquired a new position in Intercept Pharmaceuticals in the first quarter valued at approximately $4,732,000. Finally, Engineers Gate Manager LP acquired a new position in Intercept Pharmaceuticals in the first quarter valued at approximately $1,467,000. Hedge funds and other institutional investors own 76.46% of the company’s stock.

Shares of Intercept Pharmaceuticals stock opened at $47.91 on Wednesday. The stock has a market cap of $2.55 billion, a P/E ratio of -4.47 and a beta of 1.82. The stock’s 50 day simple moving average is $78.84 and its 200-day simple moving average is $88.09. Intercept Pharmaceuticals has a 1-year low of $44.50 and a 1-year high of $125.00. The company has a debt-to-equity ratio of 10.32, a current ratio of 4.19 and a quick ratio of 4.19.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported ($2.86) EPS for the quarter, beating analysts’ consensus estimates of ($2.94) by $0.08. Intercept Pharmaceuticals had a negative return on equity of 430.51% and a negative net margin of 127.53%. The firm had revenue of $72.60 million for the quarter, compared to analysts’ expectations of $69.67 million. During the same period in the prior year, the firm posted ($3.03) earnings per share. The firm’s quarterly revenue was up 39.1% on a year-over-year basis. As a group, research analysts expect that Intercept Pharmaceuticals will post -11.3 EPS for the current fiscal year.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

See Also: Find a Trading Strategy That Works

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.